Latest & greatest articles for pregabalin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pregabalin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pregabalin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pregabalin

1. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain

Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

2. Trial of Pregabalin for Acute and Chronic Sciatica. (PubMed)

Trial of Pregabalin for Acute and Chronic Sciatica. Sciatica can be disabling, and evidence regarding medical treatments is limited. Pregabalin is effective in the treatment of some types of neuropathic pain. This study examined whether pregabalin may reduce the intensity of sciatica.We conducted a randomized, double-blind, placebo-controlled trial of pregabalin in patients with sciatica. Patients were randomly assigned to receive either pregabalin at a dose of 150 mg per day that was adjusted (...) underwent randomization, of whom 108 received pregabalin and 101 received placebo; after randomization, 2 patients in the pregabalin group were determined to be ineligible and were excluded from the analyses. At week 8, the mean unadjusted leg-pain intensity score was 3.7 in the pregabalin group and 3.1 in the placebo group (adjusted mean difference, 0.5; 95% confidence interval [CI], -0.2 to 1.2; P=0.19). At week 52, the mean unadjusted leg-pain intensity score was 3.4 in the pregabalin group and 3.0

2017 NEJM

3. Pregabalin for Acute Pain: A Review of the Clinical Effectiveness

Pregabalin for Acute Pain: A Review of the Clinical Effectiveness Pregabalin for Acute Pain: A Review of the Clinical Effectiveness | CADTH.ca Find the information you need Pregabalin for Acute Pain: A Review of the Clinical Effectiveness Pregabalin for Acute Pain: A Review of the Clinical Effectiveness Published on: January 24, 2017 Project Number: RC0843-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical (...) effectiveness of pregabalin for acute pain? What is the comparative effectiveness of concurrent pregabalin and opioid use versus opioids alone for the management of acute or post-operative pain? Key Message One randomized controlled trial (RCT) demonstrated that compared to opioids alone, a single pre-operative dose of pregabalin in combination with post-operative opioids significantly reduced post-operative opioid consumption, pain scores and use of breakthrough analgesia at 48 hours. A second RCT

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

4. Pregabalin for decreasing pancreatic pain in chronic pancreatitis. (PubMed)

Pregabalin for decreasing pancreatic pain in chronic pancreatitis. Chronic abdominal pain is one of the major symptoms in people with chronic pancreatitis. The role of pregabalin in people with chronic pancreatic pain due to chronic pancreatitis is uncertain.To assess the benefits and harms of pregabalin in people with chronic abdominal pain due to chronic pancreatitis.We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library 2015, issue 6, and MEDLINE (...) difference (MD) with 95% confidence intervals (CI) with RevMan 5, based on intention-to-treat analysis.Only one study, funded by Pfizer, met the inclusion criteria for the review. A total of 64 participants (with chronic pain due to chronic pancreatitis) were randomly assigned to receive escalating doses of pregabalin (150 mg per day to 600 mg per day; 34 participants) or matching placebo (30 participants). Participants received pregabalin or placebo for three weeks on an outpatient basis; the outcomes

Full Text available with Trip Pro

2016 Cochrane

5. Gabapentin and pregabalin: major adverse effects

Gabapentin and pregabalin: major adverse effects Prescrire IN ENGLISH - Spotlight ''Gabapentin and pregabalin: major adverse effects'', 1 November 2014 {1} {1} {1} | | > > > Gabapentin and pregabalin: major adverse effects Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Gabapentin and pregabalin: major adverse effects To reduce the consequences (...) of some severe adverse effects associated with gabapentin or pregabalin, it is advisable not to expose patients to them other than in situations where these drugs have proved to be highly effective. Gabapentin and pregabalin are used in certain epilepsies and for pain in neurological diseases. Pregabalin is also used to treat anxiety disorders. According to a review of French pharmacovigilance data published in 2013, between 1995 and 2009, 2415 adverse effects linked to gabapentin or pregabalin were

2014 Prescrire

6. Pregabalin Zentiva k.s. - neuropathic pain, epilepsy, generalised anxiety disorder

Pregabalin Zentiva k.s. - neuropathic pain, epilepsy, generalised anxiety disorder 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 15 December 2016 EMA/14344/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment (...) report Pregabalin Zentiva k.s. International non-proprietary name: pregabalin Procedure No. EMEA/H/C/004277/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Assessment report EMA/14344/2017 Page 2/22 Table of contents 1. Background information on the procedure 5 1.1. Submission of the dossier 5 1.2. Steps taken for the assessment of the product 6 2. Scientific discussion 7 2.1. Introduction 7 2.2. Quality aspects 7 2.2.1

2017 European Medicines Agency - EPARs

7. Pregabalin for pain in fibromyalgia in adults. (PubMed)

Pregabalin for pain in fibromyalgia in adults. This review updates part of an earlier Cochrane review on 'Pregabalin for acute and chronic pain in adults' (Moore 2009), and considers only fibromyalgia pain.Antiepileptic drugs have been used in pain management since the 1960s. Pregabalin is an antiepileptic drug also used in management of chronic pain conditions, including fibromyalgia. Pain response with pregabalin is associated with major benefits for other symptoms, and improved quality (...) of life and function in people with chronic painful conditions.To assess the analgesic efficacy and adverse events of pregabalin for pain in fibromyalgia in adults, compared with placebo or any active comparator.We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE for randomised controlled trials from inception to May 2009 for the original review and to 16 March 2016 for this update. We also searched the reference lists of retrieved studies and reviews

Full Text available with Trip Pro

2016 Cochrane

8. Pregabalin

Pregabalin Top results for pregabalin - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for pregabalin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

9. Pregabalin, the lidocaine plaster and duloxetine in patients with refractory neuropathic pain: a systematic review

Pregabalin, the lidocaine plaster and duloxetine in patients with refractory neuropathic pain: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

10. Efficacy and Safety of Once-Daily Controlled-Release Pregabalin for the Treatment of Patients with Postherpetic Neuralgia: A Double-blind, Randomized Withdrawal, Placebo-Controlled Trial. (PubMed)

Efficacy and Safety of Once-Daily Controlled-Release Pregabalin for the Treatment of Patients with Postherpetic Neuralgia: A Double-blind, Randomized Withdrawal, Placebo-Controlled Trial. To assess efficacy and safety of once-daily controlled-release (CR) formulation of pregabalin in patients with postherpetic neuralgia.An enriched enrollment, randomized withdrawal trial, with 6-week single-blind pregabalin treatment phase and 13-week double-blind phase, where patients with ≥50% decrease (...) in mean pain score at single-blind end point from baseline were randomized (1:1) to pregabalin CR (82.5 to 660 mg/d) or placebo. Primary efficacy outcome was time to loss of therapeutic response (LTR) (<30% decrease in weekly mean pain score from single-blind baseline or discontinuation due to adverse event or lack of efficacy). Secondary efficacy outcomes included change in weekly mean pain score (1-wk recall period) at double-blind end point.In total, 801 patients were randomized and treated

2016 Clinical Journal of Pain

11. Pregabalin versus sertraline in generalized anxiety disorder. An open label study. (PubMed)

Pregabalin versus sertraline in generalized anxiety disorder. An open label study. Generalized Anxiety Disorder (GAD) is a chronic mental illness with a prevalence of 5-7% in the general population. t GAD is characterized by extreme persistent worry, mostly about minor problems, involving pathological fear with high occurrences of vegetative disturbance. GAD leads to functional impairment and a significantly reduced patient's quality of life. According to the guidelines of the World Federation (...) of Societies of Biological Psychiatry (WFSBP), the first-line treatments for GAD are Serotonin selective reuptake inhibitors (SSRIs), Selective serotonin- and norepinephrine reuptake inhibitors (SNRIs) and pregabalin, an atypical anxiolytic. In this study, both efficacy and tolerability of pregabalin were evaluated and compared with efficacy and tolerability of sertraline, an SSRI antidepressant.107 patients both male and female, aged 20-60 were included in the study. All patients were hospitalized outward

2015 European review for medical and pharmacological sciences

12. Clinical Trial Assessing the Efficacy of Gabapentin Plus B Complex (B1/B12) versus Pregabalin for Treating Painful Diabetic Neuropathy. (PubMed)

Clinical Trial Assessing the Efficacy of Gabapentin Plus B Complex (B1/B12) versus Pregabalin for Treating Painful Diabetic Neuropathy. Painful diabetic neuropathy (PDN) is a prevalent and impairing disorder. The objective of this study was to show the efficacy and safety of gabapentin (GBP) plus complex B vitamins: thiamine (B1) and cyanocobalamine (B12) compared to pregabalin in patients with moderate to severe intensity PDN.Multicenter, randomized, blind study. Two hundred and seventy

Full Text available with Trip Pro

2016 Journal of diabetes research

13. A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. (PubMed)

A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. Neuropathic pain is difficult to diagnose and difficult to treat with certainty. So the aim of the study was to evaluate comparative clinical efficacy of pregabaline with amitriptyline and gabapentin in neuropathic cancer pain. A total of 120 patients with cancer having severe neuropathic cancer pain were enrolled in the study after (...) taking approval from Institutional Ethics Committee and divided in to 4 groups: group AT-amitriptyline, group GB-gabapentin, group PG-pregabalin, and group PL-placebo. Oral morphine was used for rescue analgesic for continued pain. Pain score (Visual Analogue scale) and secondary outcome measures such as intensity of lancinating, dysesthesia, and burning on numerical rating scale, Global satisfaction score (GSS), Eastern Co-operative Oncology Group scoring (ECOG), and adverse effects were assessed

2012 The American journal of hospice & palliative care

14. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study

Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study Pregabalin and gabapentin in matched patients with peripheral neuropathic pain (...) was to assess the costs and benefits of pregabalin and gabapentin, for the treatment of adults with peripheral neuropathic pain, in routine medical practice. The authors concluded that pregabalin seemed to reduce the mean weekly intensity of pain more than gabapentin, with no significant difference in costs. The reporting and methods were satisfactory. The authors' conclusion appears to be appropriate, but highly uncertain. Type of economic evaluation Cost-effectiveness analysis, cost-utility analysis Study

2010 NHS Economic Evaluation Database.

15. Can pregabalin effectively diminish acute herpetic pain and reduce the incidence of post-herpetic neuralgia in patients who present with acute herpes zoster?

Can pregabalin effectively diminish acute herpetic pain and reduce the incidence of post-herpetic neuralgia in patients who present with acute herpes zoster? BestBets: Can pregabalin effectively diminish acute herpetic pain and reduce the incidence of post-herpetic neuralgia in patients who present with acute herpes zoster? Can pregabalin effectively diminish acute herpetic pain and reduce the incidence of post-herpetic neuralgia in patients who present with acute herpes zoster? Report (...) By: Eliane Raymond-Dufresne - PGY-3, Emergency Medicine Search checked by Katharine Wylie - Senior Informatacist Institution: Laval University, Québec, Canada Date Submitted: 23rd November 2011 Date Completed: 13th February 2012 Last Modified: 20th February 2012 Status: Green (complete) Three Part Question In [patients with new onset of herpes zoster infection], can [pregabalin] be used to [decrease the incidence of post-herpetic neuralgia and to decrease the intensity of acute herpetic pain]? Clinical

2012 BestBETS

16. A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder

A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder Boschen MJ CRD summary The review concluded that pregabalin was an effective treatment for generalised anxiety disorder compared to placebo. Given limitations in the review process as well as uncertain quality (...) of the included trials the authors conclusion may not be reliable. Authors' objectives To determine the efficacy of pregabalin for treatment of generalised anxiety disorder. Searching PubMed was searched up to December 2010 for relevant published peer-reviewed trials. Search terms were reported. References lists were searched. Study selection Randomised controlled trials (RCTs) that compared pregabalin with placebo for treatment of primary generalised anxiety disorder were eligible for inclusion in the review

2011 DARE.

17. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials

The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

18. The effect of pregabalin or duloxetine on arthritis pain: a clinical and mechanistic study in people with hand osteoarthritis (PubMed)

The effect of pregabalin or duloxetine on arthritis pain: a clinical and mechanistic study in people with hand osteoarthritis Osteoarthritis (OA) is the most prevalent arthritis worldwide and is characterized by chronic pain and impaired physical function. We hypothesized that heightened pain in hand OA could be reduced with duloxetine or pregabalin. In this prospective, randomized clinical study, we recruited 65 participants, aged 40-75 years, with a Numerical Rating Scale (NRS) for pain (...) of at least 5. Participants were randomized to one of the following three groups: duloxetine, pregabalin, and placebo. The primary endpoint was the NRS pain score, and the secondary endpoints included the Australian and Canadian Hand Osteoarthritis Index (AUSCAN) pain, stiffness, and function scores and quantitative sensory testing by pain pressure algometry. After 13 weeks, compared to placebo, ANOVA found significant differences between the three groups (P=0.0078). In the intention-to-treat analysis

Full Text available with Trip Pro

2017 EvidenceUpdates

19. Pregabalin for essential tremor. (PubMed)

Pregabalin for essential tremor. Essential tremor is one of the most common movement disorders. Treatment primarily consists of pharmacological agents. While primidone and propranolol are well-established treatments in clinical practice, they may be ineffective in 25% to 55% of patients and can produce serious adverse events in a large percentage of them. For these reasons, it is worth evaluating the treatment alternatives for essential tremor. Some specialists have suggested that pregabalin (...) could be a potentially useful agent, but there is uncertainty about its efficacy and safety.To assess the effects of pregabalin versus placebo or other treatment for essential tremor in adults.We performed a systematic search without language restrictions to identify all relevant trials up to December 2015. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, NICE, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry

Full Text available with Trip Pro

2016 Cochrane

20. Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis. (PubMed)

Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis. Generalized anxiety disorder (GAD), characterized by pervasive and highly distressing anxiety and worries, is associated with severe impairment. Although numerous agents from various drug classes are available to treat GAD, as many as 50% of patients have inadequate response, constituting an important medical frontier. In the face of this challenge, new pharmacological alternatives need to be further (...) studied aiming at clinical improvement and better quality of life for patients. To assess the efficacy of pregabalin (PGB) compared with placebo for amelioration of anxiety symptoms in patients with GAD. A systematic literature search was performed using databases such as MEDLINE and EMBASE and other sources. The main outcome was Hedges' g for continuous scores. We used a random-effects model. Heterogeneity was evaluated with the I (moderate heterogeneity was assumed if I was >50% and high

2016 International clinical psychopharmacology